Anti-ischemic Resuscitation Fluid
Small Business Information
135 WEST 41ST STREET SUITE 608, NEW YORK, NY, 10036
AbstractDESCRIPTION (provided by applicant): Inflammation after ischemia and reperfusion (I/R) injury secondary to hemorrhagic shock is responsible for significant mortality and morbidity in the United States. Available intravenous fluids administered at the incid ent scene to treat hypovolemic shock do not completely prevent ischemia and reperfusion injury. Re- initiation of blood flow causes activation of several inflammatory mediators of the cytokine type, selectins and other molecules that rapidly mobilize the i nflammatory response with subsequent global organ damage. The goal of the proposed project is to prevent or reduce the deleterious effects of ischemic damage following resuscitation by optimizing the anti-inflammatory properties of the hypertonic saline (H S) (7.5%) resuscitation solution. The approach is based on the utilization of the anti-ischemic and anti-inflammatory anti-selectin compound OC-229 developed by our laboratory, which blocks adhesion molecules such as P-, L-, and E-selectins, a1, a2-, and a 4 integrins, vascular adhesion molecule-1 (VCAM-1) and intercellular adhesion molecule-1 (ICAM-1) and of a nitroso pyrimidyl substance (EC-234) that acts as a nitric oxide donor. Our hypothesis is that this combination fluid will effectively regulate leuko cyte recruitment and overcome the inflammatory and ischemic response by modulating undesirable molecular signaling pathways. In this regard, we have clearly demonstrated in several studies that following treatment with anti- selectins, the impaired physiol ogical circulatory parameters of animals with HS were significantly improved and the survival was significantly increased in treated animals as compared to control. We propose to demonstrate, in a non-heparinized hybrid model of controlled-uncontrolled hem orrhagic shock resuscitation in the rat, an accepted model to study hypovolemic shock, that a small volume of 4 ml/kg of HS combined with anti-ischemic compounds OC-229 and/or EC-234, will: 1) have a meaningful protective physiopathologic response to hemor rhage/hypovolemia by improving the end points of mean arterial pressure, arterial blood gases and liver function response, and 2) improve protection as determined by animal survival seen at 3-7 days after hemorrhagic shock. The study will also assess the r esponse of the molecular pathways associated with hemorrhage and improved treatment. A phase II study will further characterize the anti-inflammatory signaling mechanisms associated with the effect of the solution, and study tissue distribution, cytotoxici ty, and evaluation of the physiological response to the optimal combination dose of the resuscitation fluid in a pig military-relevant model. More than 200,000 people in the U.S. die from septic shock and hemorrhagic shock each year. Trauma injury resultin g from automobile accidents, bullet or knife wounds and falls is the primary reason for development of hemorrhagic shock, and is the leading cause of death for individuals under the age of 45 in the U.S. today. The single major cause of death in potentiall y salvageable battlefield casualties and in civilian accidents is hemorrhage and hypovolemic shock. Fluid resuscitation is the cornerstone of initial therapy for nearly all forms of shock, and a critical component of therapy for the critically injured pati ent. Significant efforts have been made to improve resuscitation fluids in order to protect from the cellular, biochemical and molecular deleterious changes following hemorrhage or ischemia, but to date no significant improvement in mortality has been demo nstrated by this therapy, particularly in regard to the inflammatory consequences of hemorrhagic shock. This proposal advances new therapeutic applications to control and/or alleviate ischemia/reperfusion injury during and following resuscitation. The goal is to prevent or reduce the deleterious effects of ischemic damage following resuscitation by optimizing the anti-inflammatory properties of the hypertonic
* information listed above is at the time of submission.